In vitro infection of leukemic bone marrow with HTLV-I generates immortalized cell lines expressing T or myeloid cell phenotype.

Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

In vitro infection of leukemic bone marrow with HTLV-I generates immortalized cell lines expressing T or myeloid cell phenotype.

Leukemia. 1995 Dec;9(12):2071-81. Unique Identifier : AIDSLINE MED/96112599
Giuliani A; Vernole P; D'Atri S; Del Poeta G; D'Onofrio C; Faraoni I; Greiner JW; Bonmassar E; Graziani G; Institute of Experimental Medicine, National Council of Research; CNR, Rome, Italy.

Abstract: Leukemic bone marrow cells ( > 90% blasts) of a patient with acute myeloblastic leukemia (AML), non-treated or pretreated in vitro with a mutagenic triazene compound, were infected with HTLV-I by coculture with irradiated virus-donor cells. Immortalized, HTLV-I+, double-positive CD4/CD8 euploid T cell lines, expressing HLA class I/II monomorphic determinants, and inappropriate myeloid and progenitor cell markers (ie CD13, CD14, CD15 and CD33 antigens) were obtained. In one out of 10 triazene-pretreated samples, HTLV-I infection resulted in the appearance of a rapidly growing triploid cell line (ie MTLC1 line) showing: (1) myeloid but not lymphoid phenotype; (2) beta and delta T cell receptor in germline configuration; (3) integrated, complete and incomplete HTLV-I provirus genome (also detected in a number of MTLC1 clones); (4) a high percentage of cells positive for non-specific cross-reacting antigen (a CEA-related molecule present in myeloid cells) under the influence of gamma-interferon; (5) absence of HLA class I/II antigen expression; (6) absence of tax gene transcription. Blast cell proliferation was marginal or absent when leukemic marrow was not subjected to retroviral infection. These results show that exposure of leukemic bone marrow to HTLV-I can be followed by immortalization of T and myeloid cells. Although no data are available to establish whether tax expression played a role in the early phase of the immortalization process of MTLC1 line, tax gene product was not required for maintaining long-term growth of MTLC1 cells.

Keywords: Antigens, CD/BIOSYNTHESIS Base Sequence Bone Marrow/IMMUNOLOGY/*PATHOLOGY/VIROLOGY Cell Transformation, Viral Granulocytes/IMMUNOLOGY/PATHOLOGY Human *HTLV-I HTLV-I Infections/*PATHOLOGY Immunophenotyping Karyotyping Leukemia, Myelocytic, Acute/GENETICS/IMMUNOLOGY/*PATHOLOGY/ VIROLOGY Molecular Sequence Data Receptors, Antigen, T-Cell, alpha-beta/BIOSYNTHESIS Support, Non-U.S. Gov't T-Lymphocytes/IMMUNOLOGY/*PATHOLOGY Tumor Cells, Cultured JOURNAL ARTICLE
960830
M9681171

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .